Article Authors: Rohit Loomba, Rizwana Mohseni, K Jean Lucas, Julio A Gutierrez, Robert G Perry, James F Trotter, Robert S Rahimi, Stephen A Harrison, Veeral Ajmera, Jeffrey D Wayne, Marie O'Farrell, William McCulloch, Katharine Grimmer, Mary Rinella, Vincent Wai-Sun Wong, Vlad Ratziu, Gregory J Gores, Brent A Neuschwander-Tetri, George Kemble
Abstract
Increased de novo lipogenesis creates excess intrahepatic fat and lipotoxins, propagating liver damage in nonalcoholic steatohepatitis. TVB-2640, a fatty acid synthase inhibitor, was designed to reduce excess liver fat and directly inhibit inflammatory and fibrogenic pathways. We assessed the safety and efficacy of TVB-2640 in patients with nonalcoholic steatohepatitis in the United States.
